Home Recalls D-1247-2014
Class III · Low risk Terminated Initiated Feb 20, 2014 (13 years ago)
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored…
Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.
Why it was recalled
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
What was recalled
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2.
Recalling firm GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
Origin SC, United States
Initiated by Voluntary: Firm initiated
FDA recall number D-1247-2014
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class III · Low risk Ongoing May 14, 2026
Reason Failed Impurities/Degradation Specifications: Elevated levels of oxidative-related impurities, exceeding shelf-life specifications during stability…
Class III · Low risk Terminated Sep 9, 2020
Reason Labeling: Incorrect or Missing Package Insert: The package insert included in the finished product is for the Canadian market and is not part of the…
Class III · Low risk Terminated Aug 19, 2014
Reason Failed Dissolution Specifications and Failed Tablet Specifications: High 30 minute dissolution test and presence of broken lozenges.
Class III · Low risk Terminated Feb 20, 2014
Reason Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Class III · Low risk Terminated Feb 20, 2014
Reason Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.